We expect mean reversion/normalization in the non-FMCG business, which had seen a significant spike post-COVID. Additionally, two more tactical concerns are likely to keep the stock sideway
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.